{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:51:41Z","timestamp":1793170301463,"version":"4.5.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020171","name":"Foreign, Commonwealth & Development Office","doi-asserted-by":"crossref","award":["Project Number 300708-159"],"award-info":[{"award-number":["Project Number 300708-159"]}],"id":[{"id":"10.13039\/501100020171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funder: University of Oxford, KEMRI-Wellcome Trust Research Programme","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100006149","name":"Oxford University Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100006149","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Oxford, KEMRI-Wellcome Trust Research Programme","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"University of Oxford, KEMRI-Wellcome Trust Research Programme","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"University of Oxford, KEMRI-Wellcome Trust Research Programme","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>\n                    Although active vaccine safety surveillance (VSS) can complement passive VSS while overcoming the inherent limitations of spontaneous safety monitoring, it remains rare in sub-Saharan Africa. We conducted post-authorization active VSS of COVID-19 vaccines in Kilifi, Kenya using a cohort event monitoring study design. Participants were followed weekly over 13 weeks for adverse events. A subset was followed daily for one week for solicited systemic reactogenicity events (chills, fatigue, fever, headache, joint pain, malaise, muscle aches, nausea). The daily prevalence of reactogenicity events was compared to the 3-day pre-vaccine average using McNemar\u2019s test. The association of baseline characteristics with reactogenicity events was assessed using logistic regression. Between 28\n                    <jats:sup>th<\/jats:sup>\n                    September 2022 and 30\n                    <jats:sup>th<\/jats:sup>\n                    June 2023, 2,440 participants were enrolled into the cohort; 1,000 systematically sampled participants were included in the reactogenicity sub-study. Most were aged 17\u201339 years (1683; 69.0%) and were female (1895; 77.7%); 535 (28.2%) female participants were pregnant. The three most frequently reported reactogenicity events were fatigue (422; 44.1%), headache (370; 38.7%), and malaise (346; 36.2%); the proportion of severe events ranged from 2.3% (22; nausea) to 5.0% (48; malaise). Except for headache, the prevalence of systemic reactogenicity events was significantly higher in the first two days post-vaccination than pre-vaccination (p-values &lt;0.05). The odds of reactogenicity events were higher among non-pregnant women (adjusted odds ratio [aOR] 1.81; 95% CI 1.28-2.55) and pregnant women (aOR 1.69; 1.03-2.78) than among men, and higher among Johnson &amp; Johnson (aOR 2.05; 1.40-3.00) and Moderna (aOR 4.19; 2.34-7.51) vaccine recipients than among Pfizer vaccine recipients. The prevalence of pregnancy complications was 2.6% (95% CI 1.4-3.5%) against a background prevalence of 3\u201349%. Reactogenicity events following COVID-19 vaccination were generally non-severe and transient. There was no elevated risk of pregnancy-related complications. Addressing operational barriers is essential for enhancing the utility and feasibility of future active VSS.\n                  <\/jats:p>","DOI":"10.1371\/journal.pgph.0005080","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:32:21Z","timestamp":1763404341000},"page":"e0005080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Active vaccine safety surveillance: Experience from a prospective cohort event monitoring study of COVID-19 vaccines in Kenya"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6811-5897","authenticated-orcid":true,"given":"Don B.","family":"Odhiambo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Akech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-8935","authenticated-orcid":true,"given":"Boniface","family":"Karia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-4018","authenticated-orcid":true,"given":"Makobu","family":"Kimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6851-2546","authenticated-orcid":true,"given":"Samuel","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1185-3677","authenticated-orcid":true,"given":"Antipa","family":"Sigilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7382-8675","authenticated-orcid":true,"given":"Shirine","family":"Voller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mataza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-9121","authenticated-orcid":true,"given":"David","family":"Mang\u2019ong\u2019o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-2587","authenticated-orcid":true,"given":"Rose","family":"Jalang\u2019o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2536-0973","authenticated-orcid":true,"given":"Martha","family":"Mandale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-6422","authenticated-orcid":true,"given":"Anthony O.","family":"Etyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-5006","authenticated-orcid":true,"given":"John Anthony Gerard","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-1279","authenticated-orcid":true,"given":"Ambrose","family":"Agweyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-8889","authenticated-orcid":true,"given":"Eunice Wangeci","family":"Kagucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"4","key":"pgph.0005080.ref001","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/17512433.2015.1053391","article-title":"Pharmacovigilance in resource-limited countries","volume":"8","author":"S Olsson","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"pgph.0005080.ref002","volume-title":"Global vaccine safety blueprint: The landscape analysis","author":"World Health Organization (WHO)","year":"2012"},{"issue":"36","key":"pgph.0005080.ref003","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"TT Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"pgph.0005080.ref004","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14760584.2022.2042257","article-title":"Clinical development and approval of COVID-19 vaccines","volume":"21","author":"U Kalinke","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"pgph.0005080.ref005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-009430","article-title":"Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya","volume":"7","author":"S Orangi","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"13","key":"pgph.0005080.ref006","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.vaccine.2022.02.035","article-title":"Unmet need for COVID-19 vaccination coverage in Kenya","volume":"40","author":"SK Muchiri","year":"2022","journal-title":"Vaccine"},{"key":"pgph.0005080.ref007","unstructured":"Kier G, Stronski P. Russia\u2019s vaccine diplomacy is mostly smoke and mirrors. Cambridge Endowment for International Peace. 2021. Available from: https:\/\/carnegieendowmentorg\/2021\/08\/03\/russia-s-vaccine-diplomacy-is-mostly-smoke-and-mirrors-pub-85074"},{"key":"pgph.0005080.ref008","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard: WHO. 2023. Available from: https:\/\/covid19.who.int\/region\/afro\/country\/ke"},{"key":"pgph.0005080.ref009","article-title":"Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US","volume":"379","author":"X Li","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"pgph.0005080.ref010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.amepre.2022.09.002","article-title":"A systematic review and meta-analysis of the association between SARS-CoV-2 vaccination and myocarditis or pericarditis","volume":"64","author":"J Gao","year":"2023","journal-title":"Am J Prev Med"},{"issue":"1","key":"pgph.0005080.ref011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41541-023-00681-3","article-title":"Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination","volume":"8","author":"PDMC Katoto","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"6","key":"pgph.0005080.ref012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065687","article-title":"Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis","volume":"13","author":"A Alami","year":"2023","journal-title":"BMJ Open"},{"issue":"8","key":"pgph.0005080.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000883","article-title":"SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021","volume":"2","author":"AO Etyang","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"pgph.0005080.ref014","unstructured":"Pharmacy and poisons board of Kenya. Pharmacovigilance Electronic Reporting System (PvERS) [cited 2023 Jul 3]. Available from: https:\/\/pv.pharmacyboardkenya.org\/"},{"key":"pgph.0005080.ref015","unstructured":"WHO. Protocol template to be used as template for observational study protocols: cohort event monitoring (CEM) for safety signal detection after vaccination with COVID-19 vaccines. World Health Organization. 2021 [cited 2023 Sep 15]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/342193"},{"issue":"7005","key":"pgph.0005080.ref016","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.311.7005.619","article-title":"Probability of adverse events that have not yet occurred: a statistical reminder","volume":"311","author":"E Eypasch","year":"1995","journal-title":"BMJ"},{"key":"pgph.0005080.ref017","volume-title":"Deep Vein Thrombosis","author":"SM Waheed","year":"2025"},{"issue":"1","key":"pgph.0005080.ref018","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.201003-0436OC","article-title":"Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota","volume":"183","author":"G Li","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"pgph.0005080.ref019","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcrc.2018.07.002","article-title":"National incidence rates for Acute Respiratory Distress Syndrome (ARDS) and ARDS cause-specific factors in the United States (2006-2014)","volume":"47","author":"E Eworuke","year":"2018","journal-title":"J Crit Care"},{"issue":"9","key":"pgph.0005080.ref020","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1136\/annrheumdis-2013-203355","article-title":"Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints","volume":"73","author":"D Prieto-Alhambra","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"pgph.0005080.ref021","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"M Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"pgph.0005080.ref022","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jvacx.2024.100485","article-title":"Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally","volume":"18","author":"PA ShamaeiZadeh","year":"2024","journal-title":"Vaccine X"},{"issue":"4","key":"pgph.0005080.ref023","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/25785826.2022.2068331","article-title":"Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review","volume":"45","author":"N Asghar","year":"2022","journal-title":"Immunol Med"},{"issue":"11","key":"pgph.0005080.ref024","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1080\/21645515.2021.1963600","article-title":"Non-life-threatening adverse reactions from COVID-19 vaccine; a cross-sectional study with self-reported symptoms among Ghanaian healthcare workers","volume":"17","author":"D Serwaa","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"pgph.0005080.ref025","first-page":"473","article-title":"Prevalence of COVID-19 vaccine side effects among early-vaccinated healthcare workers in Eastern Ethiopia","volume":"32","author":"G Jarso","year":"2022","journal-title":"Ethiop J Health Sci"},{"issue":"1","key":"pgph.0005080.ref026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajic.2021.10.015","article-title":"The safety profile of COVID-19 vaccinations in the United States","volume":"50","author":"A Singh","year":"2022","journal-title":"Am J Infect Control"},{"issue":"22","key":"pgph.0005080.ref027","doi-asserted-by":"crossref","first-page":"15303","DOI":"10.3390\/ijerph192215303","article-title":"Side-Effects following Oxford\/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study","volume":"19","author":"J Onyango","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"pgph.0005080.ref028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.51847\/bCwca2qGfP","article-title":"A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: male versus female outcomes","volume":"11","author":"A Alghamdi","year":"2021","journal-title":"J Adv Pharm Educ Res"},{"issue":"16","key":"pgph.0005080.ref029","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1055\/s-0042-1748158","article-title":"COVID-19 vaccinations in pregnancy: comparative evaluation of acute side effects and self-reported impact on quality of life between pregnant and nonpregnant women in the United States","volume":"39","author":"E Brinkley","year":"2022","journal-title":"Am J Perinatol"},{"issue":"4","key":"pgph.0005080.ref030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40264-022-01151-w","article-title":"Description of Frequencies of reported adverse events following immunization among four different COVID-19 Vaccine Brands","volume":"45","author":"A Kant","year":"2022","journal-title":"Drug Saf"},{"issue":"7","key":"pgph.0005080.ref031","doi-asserted-by":"crossref","first-page":"249","DOI":"10.15585\/mmwr.mm7107e1","article-title":"Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022","volume":"71","author":"AM Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"pgph.0005080.ref032","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/14760584.2021.1986390","article-title":"COVID-19 vaccination in pregnant and lactating women: a systematic review","volume":"20","author":"R Falsaperla","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"pgph.0005080.ref033","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","article-title":"Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis","volume":"21","author":"N Sutton","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"pgph.0005080.ref034","volume-title":"Kenya Demographic and Health Survey 2022","author":"Kenya National Bureau of Statistics (KNBS) and ICF","year":"2023"},{"issue":"17","key":"pgph.0005080.ref035","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.3390\/ijerph191710537","article-title":"A Scoping Review of Preterm Births in Sub-Saharan Africa: Burden, Risk Factors and Outcomes","volume":"19","author":"A Mabrouk","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"19","key":"pgph.0005080.ref036","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"SB Black","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"pgph.0005080.ref037","doi-asserted-by":"crossref","first-page":"416","DOI":"10.5694\/mja13.11166","article-title":"Using automated text messages to monitor adverse events following immunisation in general practice","volume":"200","author":"A Leeb","year":"2014","journal-title":"Med J Aust"},{"issue":"45","key":"pgph.0005080.ref038","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1016\/j.vaccine.2023.09.037","article-title":"Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial","volume":"41","author":"PPM Nyambayo","year":"2023","journal-title":"Vaccine"},{"key":"pgph.0005080.ref039","doi-asserted-by":"crossref","first-page":"75","DOI":"10.12688\/wellcomeopenres.17533.1","article-title":"Pandemic preparedness and responsiveness of research review committees: lessons from review of COVID-19 protocols at KEMRI Wellcome Trust Research Programme in Kenya","volume":"7","author":"A Hinga","year":"2022","journal-title":"Wellcome Open Res"},{"key":"pgph.0005080.ref040","volume-title":"2023\/24 Kenya housing survey: basic report","author":"Kenya National Bureau of Statistics","year":"2024"},{"key":"pgph.0005080.ref041","volume-title":"The mobile gender gap report 2022","author":"GSM Association","year":"2022"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0005080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:32:31Z","timestamp":1763404351000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0005080"}},"subtitle":[],"editor":[{"given":"Julia","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0005080","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}